Track papers across labs, topics, and trends.
Search papers, labs, and topics across Lattice.
This study introduces Span, a censored-Poisson Bayesian latent-growth change-point detector that effectively models the detection process of circulating-tumor DNA (ctDNA) in HR+/HER2- metastatic breast cancer. By treating non-detects as left-censored observations, Span significantly improves early detection of impending disease progression, capturing nearly double the cases three months in advance compared to traditional snapshot methods. The method's robustness is validated against real-world data, demonstrating its potential to enhance clinical decision-making in cancer treatment by identifying growth patterns before they become clinically evident.
Span doubles the early detection of impending cancer progression by leveraging the information hidden in non-detects, a game-changer for monitoring ctDNA dynamics.
Circulating-tumour DNA (ctDNA) carries evidence of drug resistance months before imaging shows it, but the earliest evidence lives below the assay's limit of detection (LoD): a nascent subclone is detected only intermittently, producing a flickering sequence of faint detects and non-detects. Commercial liquid biopsies treat each draw as an independent snapshot and a non-detect as nothing. We argue a non-detect is a left-censored observation, and the pattern of non-detects and faint detects over time carries actionable evidence of growth before any single value is trustworthy. We introduce Span, a censored-Poisson Bayesian latent-growth change-point detector that models the binary detection process, accumulates a sequential generalised-likelihood-ratio statistic for an upward change-point in the per-variant detection rate, and raises a competing-risks alarm with calibrated false-alarm control. Span has no learned weights, so there is nothing to overfit. On a synthetic cohort of HR+/HER2- metastatic breast cancer on first-line CDK4/6-inhibitor plus endocrine therapy, at a matched 10% false-alarm rate, Span roughly doubles the fraction of impending progressions caught three months ahead (indolent regime: 25% vs 11% for the snapshot), with a falsifiable dose-response: large for indolent emergence, vanishing for fast emergence. A value-trajectory baseline performs identically to the snapshot, isolating the gain to the censored detection model. The survival backbone matches a Cox baseline on real breast-cancer data (GBSG-2, n=686; C-index 0.67 vs 0.68), and on a real longitudinal cohort with clean biomarkers (PBC2, n=312) the same pipeline correctly declines to win, a falsifiable boundary test confirming the mechanism is regime-specific. All ctDNA trajectories are synthetic.